Prognostic value of imaging markers from 18FDG-PET/CT in paediatric patients with Hodgkin lymphoma.
Journal
Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017
Informations de publication
Date de publication:
01 Mar 2021
01 Mar 2021
Historique:
pubmed:
12
12
2020
medline:
5
10
2021
entrez:
11
12
2020
Statut:
ppublish
Résumé
Identification of imaging prognostic parameters for early therapy personalisation to reduce treatment-related morbidity in paediatric Hodgkin lymphoma (HL). Our aim was to evaluate quantitative markers from baseline 2-[18F]fluoro-2-deoxy-d-glucose PET/CT as prognostic factors for treatment outcomes. Another goal was assessing the prognostic value of Deauville score at interim PET/CT. Twenty-one patients were prospectively enrolled. Median age was 12 years (range 6-17); 13 were female. Patients underwent PET/CT for disease staging (bPET), at the end of two cycles of chemotherapy (iPET) and after chemotherapy. A total of 173 lesions were segmented from bPET. We calculated 51 texture features for each lesion. Total metabolic tumour volume and total lesion glycolysis from bPET were calculated for response prediction at iPET. Univariate and multivariate analyses were used for optimal cut-off values to separate responders at iPET according to the Deauville score. We identified four texture features as possible independent predictors of treatment outcomes at iPET. The areas under the ROC for univariate analysis were 0.89 (95% CI, 0.75-1), 0.82 (95% CI, 0.64-1), 0.79 (95% CI, 0.59-0.99) and 0.89 (95% CI, 0.75-1). The survival curves for patients assigned Deauville scores 1, 2, 3 and X were different from those assigned a score 4, with 4-year progression free-survival (PFS) rates of 85 versus 29%, respectively (P = 0.05). We found four textural features as candidates for predicting early response to chemotherapy in paediatric patients with HL. The Deauville score at iPET was useful for differentiating PFS rates.
Identifiants
pubmed: 33306628
pii: 00006231-202103000-00011
doi: 10.1097/MNM.0000000000001337
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
306-314Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Références
Mauz-Körholz C, Metzger ML, Kelly KM, Schwartz CL, Castellanos ME, Dieckmann K, et al. Pediatric Hodgkin Lymphoma. J Clin Oncol. 2015; 33:2975–2985.
Bhakta N, Liu Q, Yeo F, Baassiri M, Ehrhardt MJ, Srivastava DK, et al. Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin’s lymphoma: an analysis from the St Jude Lifetime Cohort Study. Lancet Oncol. 2016; 17:1325–1334.
Schellong G, Riepenhausen M, Ehlert K, Brämswig J, Dörffel W, Schmutzler RK, et al. Brest cancer in young women after treatment for Hodgkin’s disease during childhood or adolescence. Dtsch Ärztebl Int. 2014; 111:3–9.
Bhatia S, Yasui Y, Robison LL, Birch JM, Bogue MK, Diller L, et al.; Late Effects Study Group. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin’s disease: report from the Late Effects Study Group. J Clin Oncol. 2003; 21:4386–4394.
Gotti M, Fiaccadori V, Bono E, Landini B, Varettoni M, Arcaini L, et al. Therapy-related late adverse events in Hodgkin’s lymphoma. Lymphoma. 2013; 2013:1–7.
Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010; 51:25–30.
Rigacci L, Vitolo U, Nassi L, Merli F, Gallamini A, Pregno P, et al.; Intergruppo Italiano Linfomi. Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol. 2007; 86:897–903.
London K, Cross S, Onikul E, Dalla-Pozza L, Howman-Giles R. 18F-FDG PET/CT in paediatric lymphoma: comparison with conventional imaging. Eur J Nucl Med Mol Imaging. 2011; 38:274–284.
Purz S, Mauz-Körholz C, Körholz D, Hasenclever D, Krausse A, Sorge I, et al. [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin’s lymphoma. J Clin Oncol. 2011; 29:3523–3528.
Furth C, Steffen IG, Amthauer H, Ruf J, Misch D, Schönberger S, et al. Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin’s lymphoma: analysis of a prospective multicenter trial. J Clin Oncol. 2009; 27:4385–4391.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin’s Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32:3059–3068.
Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET-scan in Lymphoma. Leuk Lymphoma. 2009; 50:1257–1260.
Kluge R, Kurch L, Montravers F, Mauz-Körholz C. FDG PET/CT in children and adolescents with lymphoma. Pediatr Radiol. 2013; 43:406–417.
Bakhshi S, Bhethanabhotla S, Kumar R, Agarwal K, Sharma P, Thulkar S, et al. Posttreatment PET/CT rather than interim PET/CT using Deauville criteria predicts outcome in pediatric hodgkin lymphoma: a prospective study comparing PET/CT with conventional imaging. J Nucl Med. 2017; 58:577–583.
Kumar V, Gu Y, Basu S, Berglund A, Eschrich SA, Schabath MB, et al. Radiomics: the process and the challenges. Magn Reson Imaging. 2012; 30:1234–1248.
Harrison LC, Luukkaala T, Pertovaara H, Saarinen TO, Heinonen TT, Järvenpää R, et al. Non-Hodgkin lymphoma response evaluation with MRI texture classification. J Exp Clin Cancer Res. 2009; 28:87.
Sertel O, Kong J, Catalyurek UV, Lozanski G, Saltz JH, Gurcan MN. Histopathological image analysis using model-based intermediate representation and color texture: follicular lymphoma grading. J Signal Process Syst. 2009; 55:169–183.
Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: cotswolds meeting. J Clin Oncol. 1989; 7:1630–1636.
Gonzalez RC, Woods RE. Digital Image Processing. 3rd ed. Upper Saddle River: Pearson Prentice Hall; 2008.
Haralick RM, Shanmugan K, Dinstein I. Textural features for image classification. IEEE Trans Syst Man Cybern. 1973; 3:610–621.
Tang X. Texture information in run-length matrices. IEEE Trans Image Process. 1998; 7:1602–1609.
Sun C, Wee WG. Neighboring gray level dependence matrix for texture classification. Comput Vis Graph Image Process. 1982; 23:341–352.
Amadasun M, King R. Textural features corresponding to textural properties. IEEE Trans Syst Man Cybern. 1989; 19:1264–1274.
Brooks FJ, Grigsby PW. Quantification of heterogeneity observed in medical images. BMC Med Imaging. 2013; 13:7.
Ben Bouallègue F, Tabaa YA, Kafrouni M, Cartron G, Vauchot F, Mariano-Goulart D. Association between textural and morphological tumor indices on baseline PET-CT and early metabolic response on interim PET-CT in bulky malignant lymphomas. Med Phys. 2017; 44:4608–4619.
Milgrom SA, Elhalawani H, Lee J, Wang Q, Mohamed ASR, Dabaja BS, et al. A PET radiomics model to predict refractory mediastinal hodgkin lymphoma. Sci Rep. 2019; 9:1322.
Lue KH, Wu YF, Liu SH, Hsieh TC, Chuang KS, Lin HH, Chen YH. Prognostic value of pretreatment radiomic features of 18F-FDG PET in patients with hodgkin lymphoma. Clin Nucl Med. 2019; 44:e559–e565.
Hussien AE, Furth C, Schönberger S, Hundsdoerfer P, Steffen IG, Amthauer H, et al. FDG-PET response prediction in pediatric hodgkin’s lymphoma: impact of metabolically defined tumor volumes and individualized SUV measurements on the positive predictive value. Cancers (Basel). 2015; 7:287–304.
Rogasch JMM, Hundsdoerfer P, Hofheinz F, Wedel F, Schatka I. Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin’s lymphoma. BMC Cancer. 2018; 18:1–9.
Zhou Y, Hong Z, Zhou M, Sang S, Zhang B, Li J, et al. Prognostic value of baseline 18 F-FDG PET/CT metabolic parameters in paediatric lymphoma. J Med Imaging Radiat Oncol. 2020; 64:87–95.
Prieto JC, Vallejo JA, Hatzimichael E, Fotopoulos A, Kiortsis DN, Sioka C. The contribution of metabolic parameters of FDG PET/CT prior and during therapy of adult patients with lymphomas. Ann Nucl Med. 2020; 34:707–717.
Kanoun S, Tal I, Berriolo-Riedinger A, Rossi C, Riedinger JM, Vrigneaud JM, et al. Methodological Aspects of total metabolic tumor volume calculation on baseline [18F] FDG PET to predict survival in Hodgkin lymphoma. PLoS One. 2015; 10:1–15.
Isik EG, Kuyumcu S, Kebudi R, Sanli Y, Karakas Z, Cakir FB, Unal SN. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of 18FDG-PET/CT according to ΔSUVmax, Deauville 5-point scale and IHP criteria. Ann Nucl Med. 2017; 31:660–668.
Kluge R, Chavdarova L, Hoffmann M, Kobe C, Malkowski B, Montravers F, et al. Inter-reader reliability of early FDG-PET/CT response assessment using the Deauville scale after 2 cycles of intensive chemotherapy (OEPA) in Hodgkin’s Lymphoma. PLoS One. 2016; 11:e0149072.
Barrington SF, Qian W, Somer EJ, Franceschetto A, Bagni B, Brun E, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010; 37:1824–1833.
McCarten KM, Nadel HR, Shulkin BL, Cho SY. Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma. Pediatr Radiol. 2019; 49:1545–1564.
Hasenclever D, Kurch L, Mauz-Körholz C, Elsner A, Georgi T, Wallace H, et al. qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging. 2014; 41:1301–1308.